[New perspectives in the approach to age-related macular degeneration].
The approval of aflibercept for the neovascular form of age-related macular degeneration has opened up the possibility of treating patients with fewer injections, since the drug can be administered once every two months. Aflibercept can also be used as rescue therapy in patients with suboptimal response to other antiangiogenic treatments. The present study reviews the scientific evidence on aflibercept, both in treatment-naïve patients and in those with an unsatisfactory response to conventional treatments.
Unidad de Mácula, Servicio de Oftalmología, Hospital Universitario y Politécnico La Fe, Valencia, España; Sociedad Española de la Retina y Vítreo, Instituto de Salud Carlos III, Madrid, España. Electronic address: robertogallego@comv.es.
R
R
Gallego-Pinazo
Servicio de Oftalmología, Hospital Universitario Vall d'Hebron, Barcelona, España; Red Temática de Investigación Cooperativa OFTARED, Instituto de Salud Carlos III, Madrid, España.
M A
MA
Zapata
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005136:Eye Proteins / Q000037:antagonists & inhibitors; D005500:Follow-Up Studies; D006801:Humans; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D005136:Eye Proteins; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor
Aflibercept; Age-related macular degeneration; Choroidal neovascularization; Degeneración macular asociada a la edad Neovascularización coroidea; Ranibizumab; Respondedores subóptimos; Suboptimal responders